Caribou Biosciences Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Caribou Biosciences, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue9.9934.4813.859.6012.36
Cost of Revenue3.93112.0882.2352.2634.43
Gross Profit6.0734.48-68.38-42.66-22.06
Operating Expenses
Research & Development130.15112.0882.2352.260.00
Selling, General & Administrative46.4638.4638.0224.3214.06
Operating Expenses172.68150.54120.2576.5814.06
Operating Income-166.62-116.06-106.40-66.98-36.12
Other Income/Expense
Interest Income0.0015.300.000.150.24
Interest Expense0.000.000.000.01-0.02
Other Income/Expense17.50-15.477.050.380.51
Income
Income Before Tax-149.11-101.88-99.35-66.60-36.13
Income Tax Expense-0.010.190.070.32-1.82
Net Income-149.11-102.07-99.42-66.92-34.31
Net Income - Continuous Operations-149.11-102.07-99.42-66.920.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-162.69-98.35-104.78-66.00-35.22
EBIT-149.11-101.88-106.40-66.98-36.12
Depreciation & Amortization3.933.531.620.980.90
Earnings Per Share
Basic EPS-2.00-1.00-2.00-2.00-4.00
Diluted EPS-2.00-1.00-2.00-2.00-4.00
Basic Shares Outstanding90.3273.8160.8031.668.55
Diluted Shares Outstanding90.3273.8160.8031.668.55